GEN Exclusives

More »

GEN News Highlights

More »
Apr 4, 2011

Quest Diagnostics to Launch Vermillion's Ovarian Cancer Test in India

  • Vermillion signs on Quest Diagnostics to make available in India OVA1, a diagnostic to assess the likelihood that an ovarian mass is malignant even when it is not indicated by a physician's independent clinical and radiological evaluation. The companies are targeting a launch in the second quarter of this year.

    Gail S. Page, president and CEO of Vermillion, says India “represents an outstanding market opportunity” given the approximately 350 million women in its population. "Vermillion is now poised for growth both domestically and internationally as we continue to develop our international strategy in concert with the efforts already under way in the U.S."

    OVA1 is the first protein-based in vitro diagnostic multivariate index assay (IVDMIA) cleared by the FDA. It uses software and five biomarkers—transthyretin (TT or prealbumin), apolipoprotein A-1 (Apo A-1), beta2-microglobulin (Beta2M), transferrin (Tfr), and cancer antigen 125 (CA 125 II).

    OVA1 reportedly has a sensitivity for malignancy and when used in conjunction with ultrasound, sensitivity for malignancy was 97%, according to Fred Ueland, M.D., principal investigator of the multicenter OVA1 clinical trial.

     


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Tackling Climate Change

Do you think most companies will respond positively to the People’s Climate March?